Seeking Alpha

me, myself, and i

me, myself, and i
Send Message
View as an RSS Feed
View me, myself, and i's Comments BY TICKER:
Latest  |  Highest rated
  • Gilead Sciences' (GILD) CEO John Martin Presents at Wells Fargo Healthcare Conference (Transcript) [View article]
    Brilliant, well said.
    Jun 18, 2014. 06:17 PM | 1 Like Like |Link to Comment
  • Gilead Sciences' (GILD) CEO John Martin Presents at Wells Fargo Healthcare Conference (Transcript) [View article]
    So Thor,
    What is a reasonable price to you? Are you going to give us your wisdom and set pricing on all drugs in the universe? All hail Mr. Sun.. the arbiter of WHAT a private enterprise might enjoy from the sweat of their brow. Hail to you, hail, hail, hail. You probably can't get to sleep at night because you can't wait to hear what you're going to say in the morning. You make my head hurt with your pathetic logic. I wish we lived in magic fairly la la land too.. but we don't and companies invest billions to make billions, not millions. Now grow up my unicorn chasing friend.
    Jun 18, 2014. 06:14 PM | 1 Like Like |Link to Comment
  • Gilead Sciences' (GILD) CEO John Martin Presents at Wells Fargo Healthcare Conference (Transcript) [View article]
    It's called 'what the market will bear'. US drug companies have had different pricing for their drugs in different markets for a long time. If they simply took the development cost for the drug and divided it equally accross all those needing a prescription the resulting price would certainly be cheaper for us Americans, but would be completely out of reach for people in the rest of the world. Would that make you happier?
    Jun 18, 2014. 06:10 PM | 1 Like Like |Link to Comment
  • Gilead Sciences' (GILD) CEO John Martin Presents at Wells Fargo Healthcare Conference (Transcript) [View article]
    Good response. Glad you're cured!!
    Jun 18, 2014. 05:54 PM | 1 Like Like |Link to Comment
  • Gilead Sciences' (GILD) CEO John Martin Presents at Wells Fargo Healthcare Conference (Transcript) [View article]
    Your 'stock split' comment cemented your ranking as a true dunce. A stock split is like turning a dollar bill into four quarters. You do understand that, right? Answer: no, you don't understand that. Pathetic. Next, 'price' and 'cost'... you yourself mentioned the 12 week treatment period, but then failed to mention the subsequent discussion of possibly shortening it to an 8 week treatment. Are you blind? Assuming they can shorten it to 8 weeks, that's a third less treatment time and presumably a 33% price reduction right there. Now why would GILD be working on trials of 8 week therapies? So they can boost sales? Hardly. I see a lot of people painting GILD with this brush 'profit mongers' and it really hacks me off. They are certainly working to enrich themselves and their shareholders, but most of these guys are doctors and they're attempting to do well by doing good. Your myopic brain can't figure that out though... now go read up on stock splits.
    Jun 18, 2014. 05:53 PM | 1 Like Like |Link to Comment
  • A Physician Compares Gilead's And AbbVie's Hepatitis C Products [View article]
    Ok, I can't count.. above 10 without taking off my shoes... I added two questions and forgot to edit the start... FOUR questions. ;-)
    May 14, 2014. 06:28 PM | Likes Like |Link to Comment
  • A Physician Compares Gilead's And AbbVie's Hepatitis C Products [View article]
    Mmmm... yummy tasty dividends!! ;-)

    Hey Doc,
    First off, great piece! Very much appreciated. Two questions:
    1) To be clear, those treated and cured of Hep C with Sovaldi can become reinfected at a later date if they contract it through sex, needles, etc. Correct?
    2) Any concerns or knowledge yet from MD's about those re-treats becoming breeding grounds / hosts for immune versions of a new strain of Hep C virus... even resistant to Sovaldi?
    3) Is it a fair statement that the rapid pace of development of HepC treatments recently has been because competitors have seen the magic Sovaldi uses and now know which way the path is and are working along the lines of making the same drug but in a different way so as to avoid patents? Seems unlikely this explosion of HepC drugs is a coincidence.
    4) Re the stock action, any idea why Mr Market let out a collective yawn when the earnings blow-out was announced? (most anticlimactic thing I've ever seen!)

    Thanks Doc!!
    May 14, 2014. 06:27 PM | Likes Like |Link to Comment
  • Gilead Sciences Morphs Into A Free Cash Flow Champion [View article]
    The biggest challenge seems to be the 'anti-cheerleaders' of the entities who have to deal with the surprising news that HepC can be cured and the reality that they now have to pay for same. Waxman and ESRX are going to be the albatross for the foreseeable future. I wonder if earning's beats are enough to overcome these pricks of fate. The buyback should have the most material effect, but the $7.9B on a $121B market cap is only ~6.5%, so on an $80 stock, that's $5.20 to the upside. Hardly the Babe Ruth home run I had been thinking this was going to be. I'll do my Rip Van Winkle and let my position ride for at least a year and see how it goes.
    May 8, 2014. 05:54 PM | 2 Likes Like |Link to Comment
  • Reevaluating Gilead Sciences After The Sell-Off [View article]
    I was going to say the same thing as Joe, but would add that you set the price high for a variety of reasons:
    - Patents expire, make the money while you can
    - Abbvie, Merck, and others will be releasing competition soon, so like all products, the best pricing you'll ever see is when you're alone in the market and will trend downward as time goes by. Corollary is 'you never want to be last into any market'. So again, make the money while you can

    By the way, nobody's entitled to 'do the arithmetic' on another person or companies investment and decide what is an appropriate ROI. Unless you're Waxman I suppose. ;-)
    Apr 16, 2014. 03:17 PM | Likes Like |Link to Comment
  • Texas reconsiders Sovaldi limits [View news story]
    The rationale is that the competing drugs arriving 9 months later will be cheaper.. yeah.. sure.. maybe.. by what... $1000 per regimen? Why would Abbvie or whoever's next cut their own throats by getting into a price war with GILD? Not likely. With as many patients out there as there are, there's more than enough business to go around and I see this more as a Coke vs Pepsi scenario rather than some kind of race to the bottom on pricing. While I certainly understand the dilemma, the solution flies in the face of the notion of the top priority being the patients well being and puts economics in first place, and maybe it should be. But if that's the case we're getting into the thorny debate about who pays in what, and who gets out what, if the economics are running the show. At that point we'll just organize the queue according to who's paid what's needed into the system to warrant this pay out. Simply telling everyone that they have to wait until prices come down is unfair to everyone, especially those who paid into the system (taxed in one form or the other) dearly.
    Apr 15, 2014. 06:40 PM | 1 Like Like |Link to Comment
  • Reevaluating Gilead Sciences After The Sell-Off [View article]
    LMAO... agreed @combat!! 100,000% agreed!! ;-)
    Apr 14, 2014. 03:29 PM | Likes Like |Link to Comment
  • Reevaluating Gilead Sciences After The Sell-Off [View article]
    Hedley Lamarr: My mind is a raging torrent, flooded with rivulets of thought cascading into a waterfall of creative alternatives.

    ;-) Joking aside... Good piece. Keep 'em coming!

    I just wonder why/how some of these comments from ESRX and Waxman are legal in the 1st place. How a business chooses to price it's product should not be free fodder in the media for those who are angling for a better price. If I'm hoping to get elected and I openly state that my opponent sleeps with underaged girls (lying) with the intention of improving my chances of getting elected, that's illegal (Libel), right? So, why do ESRX/Waxman get a free pass to try to leverage the bully pulpit in attempts to get a better price? Their actions should be considered libel if you consider their public statements aren't in the best interests of patients, but rather their pocketbooks. Plain and simple.
    Apr 14, 2014. 03:28 PM | Likes Like |Link to Comment
  • Reevaluating Gilead Sciences After The Sell-Off [View article]
    Humanitarian? Mmmm. More like a classic case of 'what the market will bear'. If they priced it at $80k in Egypt they simply wouldn't sell very much of it.
    Apr 14, 2014. 03:11 PM | Likes Like |Link to Comment
  • Express Scripts Trying To Shame Gilead Into Reducing Sovaldi Price: Who Is Really The Greedy One? [View article]
    I don't think Hep C will be eradicated.. too many people with out there who don't know they have it are spreading it around. I saw a good article recently and the long term market for Hep C drugs is unfortunately still limitless but as time goes on the price of Sovaldi will drop (patent expiration) and people will come to regard a Hep C diagnosis as more of a nuisance than a potential death sentence. The world will be a better place because of the work GILD's done, but first they must pay back the high price to create this marvelous drug.
    Apr 9, 2014. 05:07 PM | 2 Likes Like |Link to Comment
  • Express Scripts Trying To Shame Gilead Into Reducing Sovaldi Price: Who Is Really The Greedy One? [View article]
    Well written article. As another article I read recently also highlighted, this $300B number shines a withering light on what's wrong with Obamacare. If you have Hep C, you're signing up, right? Pay a small fee for Affordable Care Act coverage and get your $88k scrip filled. Problem with that is glaring and obvious... not enough money in the pool to pay for that. Solution? Demonize the company who spent billions bringing the product to market. Maybe Waxman's sleeping well at night thinking his saber rattling has solved something, but it's done no more to solve the problem than Obama's ACA has. Tort reform and transparency on hospital billing practices would be a better place to start. But when you look at how much money those industries spend on lobbying congress, it's easy to see why they won't take the real action needed to resolve this. Solution is term limits and ending the lobbyist bribery.. then the issues of tort reform and billing transparency can be brought into the daylight to be corrected.
    Apr 9, 2014. 03:11 PM | 6 Likes Like |Link to Comment
COMMENTS STATS
20 Comments
29 Likes